Requires reports on drug middlemen to help understand Medicare drug costs.
This bill would require the Medicare Payment Advisory Commission (MedPAC) to send two detailed reports to Congress. These reports would look into how pharmacy benefit managers (PBMs) make deals for Medicare prescription drug plans. The goal is to understand how these deals affect what people pay for their medicines and what pharmacies get paid.
Today, the Medicare Payment Advisory Commission (MedPAC) is not required to send specific reports to Congress. These reports would be about the agreements pharmacy benefit managers (PBMs) make for Medicare prescription drug plans. This means Congress does not get regular, detailed analysis on how these agreements affect drug costs. If this bill becomes law, MedPAC would be required to submit an initial report and a final report to Congress. These reports would provide in-depth analysis of PBM agreements, their trends, and their effects on what people pay for medicines and what pharmacies are reimbursed.
S 3729 · 119th Congress · January 29, 2026 · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers
1 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.